M. Alsabbagh

First name
M.
Middle name
W.
Last name
Alsabbagh
Alkabbani, W., Shah, B. R., Zongo, A., Eurich, D. T., Alsabbagh, M. W., & Gamble, J. M. (2023). Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15241
Alkabbani, W., Zongo, A., Minhas-Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. M. (2022). Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus. Diabet Med, e14858. http://doi.org/10.1111/dme.14858
Alkabbani, W., Zongo, A., Minhas-Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. M. (2021). Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study. Can J Diabetes. http://doi.org/10.1016/j.jcjd.2021.12.005
Renoux, C., Lix, L. M., Patenaude, V., Bresee, L. C., Paterson, J. M., Lafrance, J. P., et al. (2015). Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis. Clin J Am Soc Nephrol. http://doi.org/10.2215/cjn.11271114
Alkabbani, W., Zongo, A., Minhas-Sandhu, J. K., Eurich, D. T., Shah, B. R., Alsabbagh, M. W., & Gamble, J. M. (2021). Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2021-002496
Alkabbani, W., Gamble, J. M., Eurich, D. T., Minhas-Sandhu, J. K., Shah, B. R., Alsabbagh, M. W., & Zongo, A. (2021). Risk of hospitalization and death associated with Sodium Glucose Cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs. Diabetes Metab. http://doi.org/10.1016/j.diabet.2021.101305